A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

Incorporating biomarkers into standard practice enhances diagnostic accuracy, supporting confident treatment decisions and optimizing care.

Impact of Disease questionnaire (PsAID-12) scores were associated with treatment escalation, physicians primarily relied on clinical assessments when making treatment decisions.

A new test for prostate cancer developed by Irish and Swedish researchers better predicts the risks of the aggressive disease ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...